These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 24666728)
1. Detection of hepatocellular carcinoma in hepatitis C patients: biomarker discovery by LC-MS. Bowers J; Hughes E; Skill N; Maluccio M; Raftery D J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Sep; 966():154-62. PubMed ID: 24666728 [TBL] [Abstract][Full Text] [Related]
2. Targeted metabolic profiling of hepatocellular carcinoma and hepatitis C using LC-MS/MS. Baniasadi H; Gowda GA; Gu H; Zeng A; Zhuang S; Skill N; Maluccio M; Raftery D Electrophoresis; 2013 Oct; 34(19):2910-7. PubMed ID: 23856972 [TBL] [Abstract][Full Text] [Related]
3. [High-performance liquid chromatography-mass spectrometry-based serum metabolic profiling in patients with HBV-related hepatocellular carcinoma]. Zhang L; Fan Z; Kang H; Wang Y; Liu S; Shan Z Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jan; 39(1):49-56. PubMed ID: 30692066 [TBL] [Abstract][Full Text] [Related]
4. Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model. Zekri AR; Youssef AS; Bakr YM; Gabr RM; Ahmed OS; Elberry MH; Mayla AM; Abouelhoda M; Bahnassy AA World J Gastroenterol; 2016 Apr; 22(16):4168-82. PubMed ID: 27122667 [TBL] [Abstract][Full Text] [Related]
5. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS. Fitian AI; Nelson DR; Liu C; Xu Y; Ararat M; Cabrera R Liver Int; 2014 Oct; 34(9):1428-44. PubMed ID: 24661807 [TBL] [Abstract][Full Text] [Related]
6. Serum lipidomic profiling as a useful tool for screening potential biomarkers of hepatitis B-related hepatocellular carcinoma by ultraperformance liquid chromatography-mass spectrometry. Passos-Castilho AM; Carvalho VM; Cardozo KH; Kikuchi L; Chagas AL; Gomes-Gouvêa MS; Malta F; de Seixas-Santos Nastri AC; Pinho JR; Carrilho FJ; Granato CF BMC Cancer; 2015 Dec; 15():985. PubMed ID: 26680993 [TBL] [Abstract][Full Text] [Related]
7. Urinary nuclear magnetic resonance spectroscopy of a Bangladeshi cohort with hepatitis-B hepatocellular carcinoma: A biomarker corroboration study. Cox IJ; Aliev AE; Crossey MM; Dawood M; Al-Mahtab M; Akbar SM; Rahman S; Riva A; Williams R; Taylor-Robinson SD World J Gastroenterol; 2016 Apr; 22(16):4191-200. PubMed ID: 27122669 [TBL] [Abstract][Full Text] [Related]
8. Human liver tissue metabolic profiling research on hepatitis B virus-related hepatocellular carcinoma. Liu SY; Zhang RL; Kang H; Fan ZJ; Du Z World J Gastroenterol; 2013 Jun; 19(22):3423-32. PubMed ID: 23801834 [TBL] [Abstract][Full Text] [Related]
9. Serum biomarkers for early detection of hepatocellular carcinoma associated with HCV infection in egyptian patients. Zekri AR; Youssef AS; Bakr YM; Gabr RM; El-Rouby MN; Hammad I; Ahmed EA; Marzouk HA; Nabil MM; Hamed HA; Aly YH; Zachariah KS; Esmat G Asian Pac J Cancer Prev; 2015; 16(3):1281-7. PubMed ID: 25735368 [TBL] [Abstract][Full Text] [Related]
10. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry. Wang B; Chen D; Chen Y; Hu Z; Cao M; Xie Q; Chen Y; Xu J; Zheng S; Li L J Proteome Res; 2012 Feb; 11(2):1217-27. PubMed ID: 22200553 [TBL] [Abstract][Full Text] [Related]
11. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort. Xiao JF; Varghese RS; Zhou B; Nezami Ranjbar MR; Zhao Y; Tsai TH; Di Poto C; Wang J; Goerlitz D; Luo Y; Cheema AK; Sarhan N; Soliman H; Tadesse MG; Ziada DH; Ressom HW J Proteome Res; 2012 Dec; 11(12):5914-23. PubMed ID: 23078175 [TBL] [Abstract][Full Text] [Related]
12. Biomarker discovery for early detection of hepatocellular carcinoma in hepatitis C-infected patients. Mustafa MG; Petersen JR; Ju H; Cicalese L; Snyder N; Haidacher SJ; Denner L; Elferink C Mol Cell Proteomics; 2013 Dec; 12(12):3640-52. PubMed ID: 24008390 [TBL] [Abstract][Full Text] [Related]
13. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis. Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646 [TBL] [Abstract][Full Text] [Related]
14. Plasma protein biomarkers of hepatocellular carcinoma in HCV-infected alcoholic patients with cirrhosis. Ferrín G; Rodríguez-Perálvarez M; Aguilar-Melero P; Ranchal I; Llamoza C; Linares CI; González-Rubio S; Muntané J; Briceño J; López-Cillero P; Montero-Álvarez JL; de la Mata M PLoS One; 2015; 10(3):e0118527. PubMed ID: 25789864 [TBL] [Abstract][Full Text] [Related]
15. Esophageal cancer metabolite biomarkers detected by LC-MS and NMR methods. Zhang J; Bowers J; Liu L; Wei S; Gowda GA; Hammoud Z; Raftery D PLoS One; 2012; 7(1):e30181. PubMed ID: 22291914 [TBL] [Abstract][Full Text] [Related]
16. A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma. Luo P; Yin P; Hua R; Tan Y; Li Z; Qiu G; Yin Z; Xie X; Wang X; Chen W; Zhou L; Wang X; Li Y; Chen H; Gao L; Lu X; Wu T; Wang H; Niu J; Xu G Hepatology; 2018 Feb; 67(2):662-675. PubMed ID: 28960374 [TBL] [Abstract][Full Text] [Related]
17. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Chen T; Xie G; Wang X; Fan J; Qiu Y; Zheng X; Qi X; Cao Y; Su M; Wang X; Xu LX; Yen Y; Liu P; Jia W Mol Cell Proteomics; 2011 Jul; 10(7):M110.004945. PubMed ID: 21518826 [TBL] [Abstract][Full Text] [Related]
18. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. Ressom HW; Xiao JF; Tuli L; Varghese RS; Zhou B; Tsai TH; Ranjbar MR; Zhao Y; Wang J; Di Poto C; Cheema AK; Tadesse MG; Goldman R; Shetty K Anal Chim Acta; 2012 Sep; 743():90-100. PubMed ID: 22882828 [TBL] [Abstract][Full Text] [Related]
19. Serum microRNA expression profiling identifies serum biomarkers for HCV-related hepatocellular carcinoma. Li J; Jin B; Wang T; Li W; Wang Z; Zhang H; Song Y; Li N Cancer Biomark; 2019; 26(4):501-512. PubMed ID: 31658041 [TBL] [Abstract][Full Text] [Related]
20. Influence of hepatitis C virus infection on circulating levels of sICAM-1 and VEGF in patients with hepatitis C and hepatocellular carcinoma (HCC) and their role in enhancing detection of HCC. Helaly GF; Abou Shamaa LA Egypt J Immunol; 2006; 13(1):27-38. PubMed ID: 17974148 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]